Neurogene (NGNE) Free Cash Flow (2013 - 2026)

Neurogene has reported Free Cash Flow for 14 years, with the latest figure at -$26.5 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 22.73% year-over-year to -$26.5 million; the trailing twelve-month figure through Mar 2026 stood at -$82.2 million (down 15.59% YoY), and the FY2025 full-year result was -$77.3 million, down 8.34% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$26.5 million, down from -$16.5 million in the prior quarter.
• The five-year high for Free Cash Flow was -$9.1 million in Q3 2022, with the low at -$26.5 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$16.6 million across 5 years, with a median of -$16.5 million in 2025.
• The largest YoY upside for Free Cash Flow was 22.31% in 2022 against a maximum downside of 109.53% in 2022.
• Neurogene's Free Cash Flow stood at -$20.4 million in 2022, then advanced by 16.22% to -$17.0 million in 2023, then declined by 2.75% to -$17.5 million in 2024, then increased by 5.7% to -$16.5 million in 2025, then tumbled by 60.12% to -$26.5 million in 2026.
• The last three Free Cash Flow figures came in at -$26.5 million (Q1 2026), -$16.5 million (Q4 2025), and -$19.6 million (Q3 2025), per Business Quant data.